A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956 on ClinicalTrials.gov · last registry update 2026-08-06
An unusually large phase 2: 1,481 participants, more than double the 114 typical for the stage. Due to report September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Number of Participants Allocated to Each ISA. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 17 November 2023 — 2 years so far. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideZepbound, Mounjaro
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 1,481
- Started
- 2023-11-17
- Primary completion
- 2027-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of Participants Allocated to Each ISA
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.